

Express Mail Label No. _____

Dated: _____

Docket No.: 09857/0202272-US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Toshiyoshi Fujiwara et al.

Application No.: 10/520,901

Confirmation No.: 2780

Filed: January 7, 2005

Art Unit: N/A

For: ONCOLYTIC VIRUS REPLICATING
SELECTIVELY IN TUMOR CELLS

Examiner: Not Yet Assigned

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**MS Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated July 29, 2005. Applicants are submitting their response herewith within the two-month response period set to expire on September 29, 2005.


The U.S. Patent and Trademark Office has taken the position that the previous "Sequence Listing" in computer readable form did not comply with the requirements of Section 1.824 for the stated reason that it contained several raw sequence listing errors. However, we noticed that the copy of the Sequence Listing attached to the above-mentioned notice is different from the one we previously submitted in response to the Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated May 17, 2005. A copy of the documents submitted on June 29, 2005 is enclosed.

Resubmitted herewith in connection with the above-referenced patent application is a substitute, computer readable copy of the Sequence Listing that corrects the defects noted in the raw sequence listing. This is the same copy of the Sequence Listing submitted on June 29, 2005. No new matter has been added to the substitute Sequence Listing.

Applicants respectfully request the above-referenced patent application be placed upon the files for examination.


Dated: August 23, 2005

Respectfully submitted,

By  *Chris T. Mizumoto*
(53,970)

Chris T. Mizumoto

Registration No.: 42,899
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant



Application No. (if known): 10/520,901

Attorney Docket No.: 09857/0202272-US0

Pct

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV691013229-US in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on August 23, 2005
Date

Lillian Garcia
Signature

Lillian Garcia

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

- Response to Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pgs)
- A Copy of Notification (2 pgs) w/ a Copy of Error Report (7 pgs)
- Statement Pursuant to 37 CFR 1.821 (f) (2 pgs)
- A Paper Copy of Sequence Listing (4 pgs)
- One (1) Sequence Listing Diskette
- A Copy of Documents Submitted on June 29, 2005 (12 pgs)
- Return Receipt Postcard



UNITED STATES PATENT AND TRADEMARK OFFICE

C. T. Mizumoto
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/520,901	Toshiyoshi Fujiwara	09857/0202272-US0
INTERNATIONAL APPLICATION NO.		
PCT/JP03/08573		
I.A. FILING DATE	PRIORITY DATE	
07/07/2003	07/08/2002	

7278
DARBY & DARBY P.C.
P. O. BOX 5257
NEW YORK, NY 10150-5257

DUE: Sept. 29, 2005

Docketed on 8/3/05 by L19 for

Docketed without file

Attorney _____

Date Mailed: 07/29/2005

2/28/06

CONFIRMATION NO. 2780
371 FORMALITIES LETTER



OC000000016650574

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

WINSTON M ALVARADO

Telephone: (703) 308-9140 EXT 206

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.

10/520,901

INTERNATIONAL APPLICATION NO.

PCT/JP03/08573

ATTY. DOCKET NO.

09857/0202272-US0

FORM PCT/DO/EO/922 (371 Formalities Notice)

5020

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

10/520,901

Source:

PCU/10

Date Processed by STIC:

1/24/05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Mail this report with the notice.

Whitton, Bureado
National Stage Processing
Patent Specialist
(703) 305-6421

Raw Sequence Listing Error Summary

<u>ERROR DETECTED</u>	<u>SUGGESTED CORRECTION</u>	<u>SERIAL NUMBER:</u> <u>10/520, 901</u>
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1 <input type="checkbox"/> Wrapped Nucleic Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 <input type="checkbox"/> Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 <input type="checkbox"/> Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 <input type="checkbox"/> Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 <input type="checkbox"/> Variable Length	Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 <input type="checkbox"/> PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 <input type="checkbox"/> Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
8 <input type="checkbox"/> Skipped Sequences (NEW RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
9 <input type="checkbox"/> Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
10 <input type="checkbox"/> Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence	
11 <input type="checkbox"/> Use of <220> <i>FYI</i>	Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
12 <input type="checkbox"/> PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 <input type="checkbox"/> Misuse of n/Xaa	"n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid	



PCT

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/520,901

DATE: 01/24/2005
TIME: 10:01:10

Input Set : A:\PTO.YF.txt
Output Set: N:\CRF4\01242005\J520901.raw

2 <110> APPLICANT: KANSAI TLO
W--> 3 <120> TITLE OF INVENTION: Selective Replication of Tumor-specific Replication-competent Adenovirus

W--> 4 on Tumor Cells

W--> 5 <130> FILE REFERENCE: 42002JP

W--> 6 <140> CURRENT APPLICATION NUMBER: 10/520,901

7 <141> CURRENT FILING DATE: 2005-01-07

W--> 8 <160> NUMBER OF SEQ ID: 8

9 <170> SOFTWARE: PatentIn Ver. 2.1

11 <210> SEQ ID NO: 1

12 <211> LENGTH: 899

13 <212> TYPE: DNA

14 <213> ORGANISM: 293 cell

W--> 15 <400> SEQUENCE: 1

16 acaccgggac taaaaatgag acatattatc tgccacggag gtgttattac cgaagaaatg
17 gcccgcagtc ttttggacca gctgatcgaa gaggtactgg ctgataatct tccacccct
18 agccatttt aaccacctac cttcacgaa ctgtatgatt tagacgtgac gggcccccga
19 gatcccaacg aggaggcggt ttcgcagatt tttcccgact ctgtaatgtt ggcgggtcag
20 gaagggattt acttactcac ttttccggcg gcccgggtt ctccggagcc gcctcacctt
21 tcccgccagc ccgagcagcc ggagcagaga gccttgggtc cggttctat gccaaacctt
22 gtaccggagg tgatcgatct tacctgcac gaggtggct ttccacccag tgacgacgag
23 gatgaagagg gtgaggagtt tttgttagat tatgtggagc accccggca cggttgcagg
24 tcttgtcatt atcaccggag gaatacgggg gaccagata ttatgttgc gctttgttat
25 atgaggaccc gtggcatgtt tgtctacagt cctgtgtctg aacctgagcc tgagcccgag
26 ccagaaccgg agcctgcaag acctaccggc cggtctaaaa tggcgctgc tatccgtgaga
27 cggccgacat cacctgtgc tagagaatgc aatagtagta cggatagctg tgactccgg
28 cttctaaaca cacctcctga gatacaccgg gtggcccccgc tttgtcccat taaaccagg
29 gccgtgagag ttgttggcg tcgcccggct gtgaatgtt tcgaggactt gcttaacgag
30 cttgggcaac ctttggactt gagctgtaaa cgccccaggc cataagggtt aaacctgtg
32 <210> SEQ ID NO: 2
33 <211> LENGTH: 1823
34 <212> TYPE: DNA

35 <213> ORGANISM: 293 cell

same env

W--> 36 <400> SEQUENCE: 2

37 ctgacacctat ggaggcttgg gagtgtttgg aagattttc tgctgtgcgt aacttgctgg
38 aacagagctc taacagtacc tcttgggttt ggaggttct gtggggctca tccaggca
39 agtttgtctg cagaattaag gaggattaca agtggaaatt tgaagagctt ttgaaatcct
40 gtgggtgagct gtttggattct ttgaatctgg gtcaccaggc gctttccaa gagaaggctca
41 tcaagacttt ggattttcc acaccggggc gcgtgcggc tgctgttgc tttttgagtt
42 ttataaaaggta aaaaatggagc gaagaaaaccc atctgagcgg ggggtacctg ctggattttc
43 tggccatgca tctgtggaga gcggttgc gacacaagaa tcgcctgcata ctgttgcctt
44 ccgtccgccc ggcgataata ccgacggagg agcagcagca gcagcaggag gaagccaggc
45 ggcggccgca ggagcagagc ccattggacc ctagagccgg cctggaccct cggaaatgaa
46 ttttgtacag gtggctgaac tttatccaga actgagacgc attttgcacaa ttacagagga

please align
your
cumulati
totals
Per 1.822

of sequen
rules,
the totals
are aligned at
right margin

60
120
180
240
300
360
420
480
540
600
660
720
780
840
899

60

120

180

240

300

360

420

480

540

600

please align

1/24/05

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/520,901

DATE: 01/24/2005
TIME: 10:01:10

Input Set : A:\PTO.YF.txt
Output Set: N:\CRF4\01242005\J520901.raw

47 tgggcagggg ctaaaggggg taaagaggga gcggggggct tgtgaggcta cagaggaggc
48 taggaatcta gcttttagct taatgaccag acaccgtcct gagtgtatta ctttcaaca
49 gatcaaggat aattgcgcta atgagcttga tctgctggcg cagaagtatt ccatagagca
50 gctgaccact tactggctgc agccaggga tgatttttag gaggcttata gggtatatgc
51 aaagggtggca cttaggccag attgcaagta caagatcagc aaacttgtaa atatcaggaa
52 ttgttgctac atttctggga acggggccga ggtggagata gatacggagg atagggtggc
53 ctttagatgt agcatgataa atatgtggcc gggggtgctt ggcattggacg ggggtggat
54 tatgaatgtt aggtttactg gcccccaattt tageggtacg gtttccctgg ccaataccaa
55 ccttattccca cacgggtgaa gcttctatgg gtttaacaat acctgtgtgg aagcctggac
56 cgtatgttggg gttcgggct gtgccttta ctgtgtgtgg aagggggtgg tttgtcgccc
57 caaaagcagg gcttcaattt agaaatgcctt ctttggaaagg ttttgcattt gtttgcattt
58 tgagggttaac tccagggtgc gccacaatgt ggcctccgac tttttttttt tttttttttt
59 gaaaagcgtg gctgtgatta agcataacat ggtatgtggc aactgcgagg acagggcctc
60 tcagatgttggc acctgtgtgg acggcaactg tcacccgtgt aagaccattt acgttagccag
61 ccactcttcgc aaggccttggc cagtgttttga gcataacata ctgaccgcgt gtttcccttgc
62 tttgggttaac aggagggggg ttttcccttacc ttaccaatgc aatttggatc acactaagat
63 attgcttgatc cccgagagca ttttccaaatgtt gtttgcattt gtttgcattt gtttgcattt
64 gaagatctgg aagggtgttgg ggtacgttgg aacccgcacc aggtgcagac ctttgcgttt
65 tggcggttggaaa catatttagga accagccgtt gatgtgttgg gtttgcattt gtttgcattt
66 cgatcacttgg ttttgcatttgcacccgcgc ttttgcatttgcacccgcgc ttttgcatttgcacccgcgc
67 ttgaggtaactt gaaatgtgttgg ggc

660
720
780
840
900
960
1020
1080
1140
1200
1260
1320
1380
1440
1500
1560
1620
1680
1740
1800

1823

69 <210> SEQ ID NO: 3
70 <211> LENGTH: 605
71 <212> TYPE: DNA
72 <213> ORGANISM: 293 cell

W--> 73 <400> SEQUENCE: 3

74 tgcattttagg gcccggcaattt ccgcggccctt ccctcccccc ccccttaacgt tactggccgc
75 agcccgcttgg aataaggccg gtgtgcgtt gtctatatgt gatttccac catattggcc
76 tcttttggca atgtgaggggc ccggaaacctt ggccttgcgtt ttttgcacccg catttccatgg
77 ggtctttccc ctctcgccaa aggaatgcattt ggtctgttgcattt atgtcgatgcattt ggaaggcgtt
78 cctctggaaatgttccatgg acaaacaacgtt tctgtgttgcattt ccctttgcgtt gcaacggccatgg
79 ccccccacccgtt ggcacagggtt cctctggccgc caaaagccac gtgtataaga tacacccgtt
80 aaggccggcac aaccccaatgtt ccacccgttgcattt agttggatag ttgtggaaag agtcaaatgg
81 ctctccatggca ggttatttgcattt caagggggttgcattt aaggatgcattt agaagggtacc ccatttgcattt
82 gatctgttgcatttccatgg gtttgcacccgttgcattt ttttgcatttgcattt gtttgcatttgcattt
83 cgtcttagggcc cccggaaatccca cggggacgttgcattt gtttgcatttgcattt gtttgcatttgcattt
84 tgccca

60
120
180
240
300
360
420
480
540
600

605

86 <210> SEQ ID NO: 4
87 <211> LENGTH: 455
88 <212> TYPE: DNA
89 <213> ORGANISM: 293 cell

W--> 90 <400> SEQUENCE: 4

91 tggccccccttcc ctcgggttac cccacaggctt agggccgttgc gaccccttcgc cgttggggcc
92 ctcgggttgcgttcccttgcacc ctggggagccgc gaggccggccgc cggggccggccgc agcgcggcc
93 agaccccccgg gtcggcccccgg agcagctgttgc ctgttgcgttgc caggccggcc tccctgttgc
94 ttccggggccca cagacggccca ggaccggccgtt cccacccgttgc cggaggccgtt gggaccggcc
95 gcacccgttcc tggcccccgttca ctttccatgttgc ccgccttcgc cgcgcggacc cccggccgttcc
96 cccacccgttcc cccgggttccca gggccaggcc cccatggcc cttccatgttgc cccggccgttcc
97 ttccggccgc cccggcccttcc ctcggccgttgc cggatgttgc gtcgttgcgttgc

60
120
180
240
300
360
420

RAQUENCE LISTING
PATENT APPLICATION: US/10/520,901

DATE: 01/24/2005
TIME: 10:01:10

Input Set : A:\PTO.YF.txt
Output Set: N:\CRF4\01242005\J520901.raw

98 gcacgtggga agccctggcc ccggccaccc ccgcgcg 455
100 <210> SEQ ID NO: 5
101 <211> LENGTH: 20
102 <212> TYPE: DNA
103 <213> ORGANISM: 293 cell
W--> 104 <400> SEQUENCE: 5
105 acaccgggac taaaaatgag 20
107 <210> SEQ ID NO: 6
108 <211> LENGTH: 21
109 <212> TYPE: DNA
110 <213> ORGANISM: 293 cell
W--> 111 <400> SEQUENCE: 6
112 cacaggtta caccttatgg c 21
114 <210> SEQ ID NO: 7
115 <211> LENGTH: 20
116 <212> TYPE: DNA
117 <213> ORGANISM: 293 cell
W--> 118 <400> SEQUENCE: 7
119 ctgacccat ggaggcttgg 20
121 <210> SEQ ID NO: 8
122 <211> LENGTH: 21
123 <212> TYPE: DNA
124 <213> ORGANISM: 293 cell
W--> 125 <400> SEQUENCE: 8
126 gccccacacat ttcaatccat c 21

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/520,901

DATE: 01/24/2005
TIME: 10:01:11

PYI
Input Set : A:\PTO.YF.txt
Output Set: N:\CRF4\01242005\J520901.raw

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 3
Seq#:2; Line(s) 37,38,39,40,41,42,43,46,48,49,50,53,54,55,56,57,58,61,62,63
Seq#:2; Line(s) 66
Seq#:3; Line(s) 74,75,76,77,81,82,83
Seq#:4; Line(s) 91,95,97

VERIFICATION SUMMARY
PATENT APPLICATION: US/10/520,901

DATE: 01/24/2005
TIME: 10:01:11

Input Set : A:\PTO.YF.txt
Output Set: N:\CRF4\01242005\J520901.raw

L:3 M:283 W: Missing Blank Line separator, <120> field identifier
L:5 M:283 W: Missing Blank Line separator, <130> field identifier
L:6 M:283 W: Missing Blank Line separator, <140> field identifier
L:8 M:283 W: Missing Blank Line separator, <160> field identifier
L:15 M:283 W: Missing Blank Line separator, <400> field identifier
L:36 M:283 W: Missing Blank Line separator, <400> field identifier
L:73 M:283 W: Missing Blank Line separator, <400> field identifier
L:90 M:283 W: Missing Blank Line separator, <400> field identifier
L:104 M:283 W: Missing Blank Line separator, <400> field identifier
L:111 M:283 W: Missing Blank Line separator, <400> field identifier
L:118 M:283 W: Missing Blank Line separator, <400> field identifier
L:125 M:283 W: Missing Blank Line separator, <400> field identifier

Atty Docket No.: 09857/0202272-US0

Inventor: Toshiyoshi Fujiwara et al.

Appn: 10/520,901-Conf. Filed: Jan. 7, 2005

Title: ONCOLYTIC VIRUS REPLICATING SELECTIVELY
IN TUMOR CELLS

Documents:

Certificate of Express Mailing Under 37 CFR 1.10 (1 pg)

Response to Notice to File Missing parts of application (2 pp)

Copy of Notice (2 pp)

1 Sequence Listing Diskette

Sequence Listing Paper Copy (4 pp)

Sequence Listing Transmittal (2 pp)

Via: Express Mail: Airbill No. *441165040-us*

Sender Initials: CTM/mch Date: June 29, 2005

B.W. Lee

Application No. (if known): 10/520,901

Attorney Docket No.: 09857/0202272-US0

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 441165040-us in an envelope addressed to:

EV 441165040-us
MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on June 29, 2005
Date

B.W. Lee

Signature

B.W. Lee

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Response to Notice to File Missing Parts of Application (2 pp)
Copy of Notice (2 pp)
Statement Pursuant to 37 CFR 1.821(f)(2 pp)
Paper copy of Sequence Listing (4 pp)
1 Sequence Listing Diskette
Return Receipt Postcard

Express Mail Label No.

Dated: _____

Docket No.: 09857/0202272-US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Toshiyoshi Fujiwara et al.

Application No.: 10/520,901

Confirmation No.: 2780

Filed: January 7, 2005

Art Unit: N/A

For: ONCOLYTIC VIRUS REPLICATING
SELECTIVELY IN TUMOR CELLS

Examiner: Not Yet Assigned

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

MS Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice to File Missing Parts of Application – Filing Date Granted mailed May 17, 2005, Applicant respectfully submits a Sequence Listing Diskette, a Sequence Listing Paper Copy, a Statement Pursuant to 37 CFR 1.821(f), and Part 2 Copy of Notice.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: June 29, 2005

Respectfully submitted,

By  *Chris T. Mizumoto*
(53,970)

Registration No.: 42,899
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

M. Hasegawa.

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/520,901	Toshiyoshi Fujiwara	09857/0202272-US0
INTERNATIONAL APPLICATION NO.		PCT/JP03/08573
LA. FILING DATE	PRIORITY DATE	
07/07/2003	07/08/2002	

7278
 DARBY & DARBY P.C.
 P. O. BOX 5257
 NEW YORK, NY 10150-5257

DUE: July 17, 2005
 Docketed on 5/24/05 by LG for
 Docketed without file
 Attorney _____

Date Mailed: 05/17/2005
12/17/05

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

WINSTON M ALVARADO

Telephone: (703) 308-9140 EXT 206

PART 1 - ATTORNEY/APPLICANT CO

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/520,901	PCT/JP03/08573	09857/0202272-US0

FORM PCT/DO/EO/922 (371 Formalities Notice)

Express Mail Label No.

Dated: _____

Docket No.: 09857/0202272-US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Toshiyoshi Fujiwara et al.

Application No.: 10/520,901

Confirmation No.: 2780

Filed: January 7, 2005

Art Unit: N/A

For: **ONCOLYTIC VIRUS REPLICATING
SELECTIVELY IN TUMOR CELLS**

Examiner: Not Yet Assigned

STATEMENT PURSUANT TO 37 CFR 1.821(f)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Submitted herewith for filing in connection with the above-referenced patent application is a labeled, computer readable copy of the Sequence Listing included in the application.

The sequence information in paper copy of the Sequence Listing contained on pages 1 to 4 of said Sequence Listing, as required by 37 CFR 1.821(c), and the sequence information in computer readable form of the Sequence Listing described above, as required by 37 CFR 1.821(e), are the same as required by 37 CFR 1.821(f). No new matter is added.

Early favorable consideration of the patent application is respectfully solicited.

Dated: June 29, 2005

Respectfully submitted,

By  FLYNN BARRISON
(53,970)

Chris T. Mizumoto

Registration No.: 42,899
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant

00450122.TXT
SEQUENCE LISTING

<110> Fujiwara, Toshiyuki
Tanaka, Noriaki
Kyo, Satoru
Shirakiya, Yoshiko
Kawashima, Takeshi

<120> ONCOLYTIC VIRUS REPLICATING SELECTIVELY IN TUMOR CELLS

<130> 09857/0202272-US0

<140> 10/520,901
<141> 2005-01-07

<150> PCT/JP2003/008573
<151> 2003-07-07

<150> 2002-198941
<151> 2002-07-08

<160> 8

<170> PatentIn version 3.2

<210> 1
<211> 899
<212> DNA
<213> adenovirus

<400> 1
acaccgggac tgaaaatgag acatattatc tgccacggag gtgttattac cgaagaaatg 60
gccgccagtc ttttggacca gctgatcgaa gaggtactgg ctgataatct tccacccct 120
agccattttgc aaccacccac cttcacgaa ctgtatgatt tagacgtgac ggccccgaa 180
gatcccaacg aggaggcggt ttcgcagatt tttcccgact ctgtaatgtt ggccgtgcag 240
gaagggatttgc acttactcac ttttccgccc gcgcgggtt ctccggagcc gcctcacctt 300
tcccgccagc ccgagcagcc ggagcagaga gccttgggtc cggttctat gccaaacctt 360
gtaccggagg tgatcgatct tacctgccac gaggctggct ttccacccag tgacgacgag 420
gatgaagagg gtgaggagtt tggatcgatct tatgtggagc accccgggca cggttgcagg 480
tcttgcatt atcaccggag gaatacgggg gacccagata ttatgtgttc gctttctat 540
atgaggacccgtt gtggcatgtt tggatcgatct cctgtgtctg aacctgagcc tgagcccgag 600
ccagaaccgg agcctgcaag acctaccgc cgtcctaaaa tggcgctgc tatcctgaga 660
cgcccgacat cacctgtgtc tagagaatgc aatagtagta cggatagctg tgactccggt 720
ccttctaaca cacccctga gatacaccgg gtgggtccgc tggatcgatct taaaccagg 780
gccgtgagag ttgggtggcg tcgcccaggct gtggatcgatct tcgaggactt gcttaacgag 840
cctggggcaac ctttggactt gagctgtaaa cgcccccaggc cataagggtgt aaacctgtg 899

<210> 2

00450122.TXT

<211> 1823
 <212> DNA
 <213> adenovirus

<400> 2		
ctgacctcat ggaggcttgg gagtgtttgg aagattttc tgctgtgcgt aacttgctgg	60	
aacagagctc taacagtacc tcttggttt ggaggtttct gtggggctca tcccaggcaa	120	
agttagtctg cagaattaag gaggattaca agtggaaatt tgaagagctt ttgaatcct	180	
gtggtagct gtttgattct ttgaatctgg gtcaccaggc gctttccaa gagaaggtca	240	
tcaagacttt ggattttcc acaccggggc gcgcgcggc tgctgttgc ttggat	300	
ttataaagga taaatggagc gaagaaaccc atctgagcgg ggggtacctg ctggat	360	
tggccatgca tctgtggaga gcgggtgtga gacacaagaa tcgcctgcta ctgtgtctt	420	
ccgtccgccc ggcataata ccgacggagg agcagcagca gcagcaggag gaagccaggc	480	
ggccggccgca ggacggcggc ccatggaaacc cgagagccgg cctggaccct cggaaatgaa	540	
tgttgacag gtggctgaac tgtatccaga actgagacgc attttgacaa ttacagagga	600	
tggcagggg ctaaaggggg taaagagggg gcggggggct tgtgaggcta cagaggaggc	660	
taggaatcta gcttttagct taatgaccag acaccgtcct gagtgtatata ctttcaaca	720	
gatcaaggat aattgcgcta atgagcttga tctgtggcg cagaagtattt ccatacagca	780	
gctgaccact tactggctgc agccaggggg tgatttgag gaggctattt gggtatatgc	840	
aaagggtggca ctttaggccag attgcaagta caagatcagc aaacttgtaa atatcaggaa	900	
ttgttgctac atttctggaa acggggccga ggtggagata gatacggagg atagggtggc	960	
ctttagatgt agcatgataa atatgtggcc ggggtgtctt ggcattggacg ggtggttat	1020	
tatgaatgta aggttactg gcccccaattt tagcggtacg gtttcttgg ccaataccaa	1080	
ccttattccta cacgggttaa gcttctatgg gtttaacaat acctgtgtgg aagcctggac	1140	
cgatgttaagg gttcggggct gtgcctttta ctgctgtgg aaggggggtgg tgtgtcgccc	1200	
caaaagcagg gcttcaatta agaaatgcct ctttggaaagg tgtaccttgg gtatcctgtc	1260	
tgagggttaac tccagggtgc gccacaatgt ggcctccgac tgtggttgc tcatgttagt	1320	
gaaaagcgtg gctgtgatta agcataacat ggtatgtggc aactgcgagg acaggccctc	1380	
tcagatgtcg acctgtctgg acggcaactg tcacctgtg aagaccattc acgttagccag	1440	
ccactctcgc aaggcctggc cagtgtttga gcataacata ctgacccgct gttccttgca	1500	
tttgggttaac aggagggggg ttttcctacc ttaccaatgc aatttgagtc acactaagat	1560	
attgcttggc cccgagagca tgtccaagggt gaacctgaac ggggtgtttg acatgaccat	1620	
gaagatctgg aaggtgtga ggtacgtga gacccgcacc aggtgcagac cctgcgagtg	1680	
tggcggtaaa catatttagga accagcctgt gatgctggat gtgaccggagg agctgaggcc	1740	

00450122.TXT

cgatcacttg	gtgctggcct	gcacccgcgc	ttagttggc	tctagcgatg	aagatacaga	1800
ttgaggtact	gaaatgtgtg	ggc				1823

<210> 3
 <211> 605
 <212> DNA
 <213> picornavirus

<400> 3						
tgcatctagg	gcggccaatt	ccgccccctct	ccctcccccc	cccctaacgt	tactggccga	60
agccgcttgg	aataaggccg	gtgtgcgttt	gtctatatgt	gatttccac	catattgccg	120
tctttggca	atgtgagggc	ccggaaacct	ggccctgtct	tcttgacgag	cattcctagg	180
ggtctttccc	ctctcgccaa	aggaatgcaa	ggtctgttga	atgtcgtgaa	ggaagcagtt	240
cctcttggaa	cttcttgaag	acaaacaacg	tctgtagcga	ccctttgcag	gcagcggAAC	300
cccccacctg	gcgacaggtg	cctctgcggc	caaaagccac	gtgtataaga	tacacctgca	360
aaggcggcac	aaccccagtg	ccacgttgtg	agttggatag	ttgtggaaag	agtcaaatgg	420
ctctcctcaa	gcgtattcaa	caaggggctg	aaggatgccc	agaaggatacc	ccattgtatg	480
ggatctgatc	tggggcctcg	gtgcacatgc	tttacatgtg	tttagtcgag	gttaaaaaaa	540
cgtctaggcc	ccccgaacca	cggggacgtg	gttttccccc	gaaaaaacacg	atgataagct	600
tgccca						605

<210> 4
 <211> 455
 <212> DNA
 <213> Homo sapiens

<400> 4						
tggccctcc	ctcgggttac	cccacagcct	aggccgattc	gacctctctc	cgctggggcc	60
ctcgctggcg	tccctgcacc	ctgggagcgc	gagcggcgcg	cgggcgggga	agcgcggccc	120
agaccccccgg	gtccgcccgg	agcagctgcg	ctgtcggggc	caggccgggc	tcccagtgg	180
ttcgcgggca	cagacgccc	ggaccgcgct	ccccacgtgg	cggagggact	ggggacccgg	240
gcacccgtcc	tgccccttca	ccttccagct	ccgcctcctc	cgcgcggacc	ccgccccgtc	300
ccgacccctc	ccgggtcccc	ggcccagccc	cctccgggccc	ctcccagccc	ctccccttcc	360
tttccgcggc	cccgcctct	cctcgcggcg	cgagttcag	gcagcgctgc	gtcctgctgc	420
gcacgtggga	agcccctggcc	ccggccacccc	ccgcg			455

<210> 5
 <211> 20
 <212> DNA
 <213> artificial

<220>

<223> primer

<400> 5

acaccgggac tgaaaatgag

20

<210> 6

<211> 21

<212> DNA

<213> artificial

<220>

<223> primer

<400> 6

cacaggttta caccttatgg c

21

<210> 7

<211> 20

<212> DNA

<213> artificial

<220>

<223> primer

<400> 7

ctgacacctat ggaggcttgg

20

<210> 8

<211> 21

<212> DNA

<213> artificial

<220>

<223> primer

<400> 8

gcccacacat ttcagtacct c

21

BEST AVAILABLE COPY

Sequence Listing

Applicant: Toshiyoshi Fujiwara et al.
Date Saved to Disk: June 29, 2005
Title: ONCOLYTIC VIRUS REPLICATING
SELECTIVELY IN TUMOR CELLS
Reference/Docket No.: 09857/0202272-US0
Appl. No.: 10/520,901
Filed: January 7, 2005
Operating System: Windows NT 4.0